Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366247 | 0.86 | KDM4E (0.42) | MEN1KMT2ASLC6A7MAPT | |
| SCHEMBL27848382 | 0.81 | SLC6A7 (0.42) | MEN1KMT2AP2RY12SLC6A7MAPT | |
| SCHEMBL2366420 | 0.81 | KDM4E (0.38) | SLC6A7 | |
| SCHEMBL2366289 | 0.81 | SLC6A7 (0.44) | MEN1KMT2AP2RY12SLC6A7MAPT | |
| SCHEMBL14687427 | 0.81 | ALDH1A1 (0.48) | MEN1KMT2AP2RY12SLC6A7MAPT | |
| SCHEMBL2365786 | 0.81 | SLC6A7 (0.48) | MEN1KMT2AP2RY12SLC6A7MAPT | |
| SCHEMBL27848262 | 0.81 | MEN1 (0.42) | MEN1KMT2AP2RY12MAPT | |
| SCHEMBL2365914 | 0.80 | MEN1 (0.43) | MEN1KMT2AP2RY12SLC6A7MAPT | |
| SCHEMBL2366183 | 0.79 | KMT2A (0.35) | MEN1KMT2AP2RY12SLC6A7MAPT | |
| SCHEMBL2366191 | 0.79 | KMT2A (0.35) | MEN1KMT2AP2RY12SLC6A7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | MEN1 2896/4885KMT2A 800/4885P2RY12 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.